Valneva announces positive initial results for the phase 3 trial VLA1553-302, to assess clinical lot homogeneity of its single injection chikungunya vaccine candidate, VLA1553.
The trial indeed met its primary endpoint, showing that three consecutively manufactured batches elicited equivalent immune responses, measuring neutralizing antibody titers 29 days after vaccination.
The batch homogeneity trial will continue until the final six-month analysis, the final results of the long-awaited trial in the second quarter of 2022. The company plans to initiate the submission dossier to the US FDA. next Year.
Copyright (c) 2021 CercleFinance.com. All rights reserved.